Changes in high-ranking execs poised to deepen at Karyopharm; Tillman Gerngross-chaired biotech promotes new medical chief to CEO
→ Round and round the executive carousel turns at Karyopharm as Reshma Rangwala replaces Jatin Shah as CMO, a month removed from the FDA pulling the rug out from under selinexor’s chances in endometrial cancer by calling for a new trial first. The remnants of the old guard at Karyopharm continue to peel off, with co-founder and CSO Sharon Shacham now stepping down alongside senior clinical advisor and ex-CEO Michael Kauffman starting May 31.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.